Single Cell ’analyzes of hematological malignancies, in particular acute myeloid leukemia (AML).
AML is an example of a heterogeneous group of hematologic malignancies with a variable response to therapy. The heterogeneity of AML is illustrated by the different (combinations of) mutations that occur with AML. Based on these mutations, an estimate can be made of the prognosis of the AML patient. However, despite the fact that the determination of the prognosis has greatly improved in recent decades, there is still much to be gained.
Residual disease during therapy is a very good predictor for getting a recurrence for various haematological malignancies. We have recently demonstrated that the use of next generation sequencing in residual disease detection greatly improves the quantitative prediction of a recurrence.
The analyzes in the above study were performed on the bulk of the AML cells.
Analyzes of DNA abnormalities at the level of a single cell will ultimately be necessary to determine which cells within a heterogeneous population are critically important for the return of the AML.